Key result
In a review of 39 cases of laryngeal synovial sarcoma, no clinicopathologic factors or specific treatment regimens were associated with improved overall survival or lower rates of recurrence.
Why the study?
Primary laryngeal synovial sarcoma is extremely rare with no well-defined guidelines to direct investigation and management, leaving treatment largely based on limb synovial sarcoma.
Do specific clinicopathologic factors or treatment regimens improve overall survival or reduce recurrence in patients with primary laryngeal synovial sarcoma?
Systematic Review (n=39)
Do specific clinicopathologic factors or treatment regimens improve overall survival or reduce recurrence in patients with primary laryngeal synovial sarcoma?
There is significant heterogeneity in the treatment of primary laryngeal synovial sarcoma, with no specific regimen showing improved survival, highlighting the need for standardized reporting and formal clinical guidelines.
Answers are grounded in this paper and cite their sources.
No prognostic factors or regimens improve laryngeal synovial sarcoma outcomes; leaves open standardized reporting and prospective studies to guide management.
Primary laryngeal synovial sarcoma is an extremely rare tumor predominantly affecting young adults. There are currently no well-defined guidelines to direct investigation and management, and treatment is largely based on what is known for synovial sarcoma of the upper and lower limbs. This PROSPERO-registered study aims to review the diagnostic methods, treatment regimens, and survival outcomes for patients with synovial sarcoma of the larynx. A systematic search of databases Medline, Embase, SCOPUS, and Web of Science was undertaken in December 2017. The literature search identified 1031 potentially relevant studies, and after the deletion of duplicates and excluded papers, 98 full-text articles were screened. A total of 39 cases were reviewed from 32 studies in the data extraction. The average age at the time of laryngeal synovial sarcoma diagnosis was 32 years (range, 11-79 years). In all cases (n = 39), patients underwent wide surgical excision, with 20 patients requiring a partial or total laryngectomy. A total of 18 patients received adjuvant and 3 received neoadjuvant radiotherapy. Chemotherapy was used in 10 cases, with ifosfamide the most frequently used agent. There was considerable variability in the order and combinations of the abovementioned treatments. No clinicopathologic factors or treatment regimens were associated with improved overall survival or lower rate of recurrence. There is a paucity of literature and heterogeneity in clinical approaches to this highly aggressive sarcoma. Reporting of cases must be standardized and formal guidelines must be established to guide clinical management.
No takes yet. Share an insight, caveat, or question.
Shein et al. (2019) conducted a systematic review in Primary laryngeal synovial sarcoma (n=39). Various treatments (surgical excision, radiotherapy, chemotherapy) was evaluated on Overall survival and rate of recurrence. In a review of 39 cases of laryngeal synovial sarcoma, no clinicopathologic factors or specific treatment regimens were associated with improved overall survival or lower rates of recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: